(IMAB) – Business Wire
-
Genexine’s long-acting growth hormone meets Phase 3 primary endpoint
-
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
-
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
-
Ferring Announces New Collaboration for Development of Olamkicept
-
Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer
-
Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation
-
Citi Appointed as Depositary Bank for I-Mab’s Sponsored ADR Program
Back to IMAB Stock Lookup
